HCC
Oncology · 2008–2025
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| nivolumab First-line treatment of patients with advanced (unresectable) Barcelona Clinic Liver Cancer (BCLC) Stage A, Stage B or Stage C hepatocellular carcinoma in… | Jul 2025 | Not recommended | input received Liver Foundation · Pancare Foundation · Rare Cancers Australia · Medical Oncology Group |
| durvalumab + tremelimumab First-line treatment of patients with advanced (unresectable) Barcelona Clinic Liver Cancer (BCLC) Stage B or Stage C hepatocellular carcinoma (HCC). | May 2025 | Recommended with restriction | input received Medical Oncology Group · Rare Cancers Australia |
| atezolizumab Subcutaneous injection formulation for five oncology indications: locally advanced or metastatic NSCLC, stage IV (metastatic) NSCLC, extensive-stage small cell… | Mar 2024 | Recommended with restriction | input received Rare Cancers Australia · Lung Foundation Australia |
| atezolizumab Treatment of patients with unresectable locally advanced or metastatic Barcelona Clinic Liver Cancer (BCLC) stage B or stage C hepatocellular carcinoma (HCC)… | Jul 2020 | Recommended with restriction | input received Gastroenterological Society of Australia · Rare Cancers Australia · Hepatitis Australia · Medical Oncology Group |
| cabozantinib Treatment of patients with Barcelona-Clinic Liver Cancer (BCLC) stage B or C advanced hepatocellular carcinoma (HCC), WHO performance status ≤1 and Child-Pugh… | Jul 2019 | Not recommended | none received |
| regorafenib Treatment of patients with unresectable hepatocellular carcinoma (HCC) who have progressed on first-line treatment with a tyrosine kinase inhibitor (TKI). | Jul 2019 | Not recommended | none received |
| lenvatinib Treatment of unresectable hepatocellular carcinoma (Barcelona Clinic Liver Cancer stage B or stage C) as first-line therapy in patients not suitable for… | Jul 2018 | Deferred | input received Medical Oncology Group · Australian Institute |
| regorafenib Treatment of patients with unresectable hepatocellular carcinoma (HCC) who progressed following treatment with sorafenib. | Mar 2018 | Not recommended | none received |
| lenvatinib First-line treatment of patients with advanced (unresectable) Barcelona Clinic Liver Cancer stage B or stage C hepatocellular carcinoma. | Nov 2018 | Recommended with restriction | none received |
| regorafenib Treatment of patients with unresectable hepatocellular carcinoma (HCC) who progressed following treatment with sorafenib. | Nov 2018 | Not recommended | none received |
| sorafenib tosylate Initial and continuing treatment of advanced hepatocellular carcinoma in patients with unresectable disease, specifically Barcelona Liver Clinic Cancer (BCLC)… | Jul 2008 | Recommended with restriction | no section in document |
| sorafenib tosylate Initial and continuing treatment of advanced hepatocellular carcinoma in patients with unresectable disease, BCLC Stage C, WHO performance status ≤2, and Child… | Jul 2008 | Recommended with restriction | no section in document |
Who spoke
Rare Cancers Australia · Medical Oncology Group · Gastroenterological Society of Australia · Hepatitis Australia · Lung Foundation Australia · Australian Institute · Liver Foundation · Pancare Foundation
What the PBS pays
$620M in government benefit over 2024–25, across 64,377 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| nivolumab; ipilimumab | $199M |
| durvalumab and tremelimumab | $175.6M |
| atezolizumab | $156.8M |
| cabozantinib | $55.8M |
| lenvatinib | $31.4M |
| sorafenib | $0.7M |
| sorafenib tosylate | $0.7M |
Appraised elsewhere
NICE, in England and Wales, has appraised 8 technologies for this condition, recommending 7 . A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| durvalumabDurvalumab with tremelimumab for untreated advanced or unresectable hepatocellular carcinoma | TA1090 | recommended restricted | 2025-08 |
| cabozantinibCabozantinib for previously treated advanced hepatocellular carcinoma | TA849 | recommended restricted | 2022-12 |
| selective internal radiation therapiesSelective internal radiation therapies for treating hepatocellular carcinoma | TA688 | recommended restricted | 2021-03 |
| atezolizumabAtezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinoma | TA666 | recommended restricted | 2020-12 |
| ramucirumabRamucirumab for treating unresectable hepatocellular carcinoma after sorafenib (terminated appraisal) | TA609 | terminated | 2019-10 |
| regorafenibRegorafenib for previously treated advanced hepatocellular carcinoma | TA555 | recommended restricted | 2019-01 |
| lenvatinibLenvatinib for untreated advanced hepatocellular carcinoma | TA551 | recommended restricted | 2018-12 |
| sorafenibSorafenib for treating advanced hepatocellular carcinoma | TA474 | recommended restricted | 2017-09 |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 5 of 10 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.